Montelukast
Monkasta is a Leukotriene Receptor Antagonist, which Blocks the Action of Substances called Leukotrienes.
Leukotrienes Cause the Airway to Narrow and Swell. By Blocking the Action of Leukotrienes, Monkasta Relieves the Symptoms of Asthma and Helps Control Asthma.
The Doctor has Prescribed Monkasta to Treat Asthma in the Child, to Prevent Asthma Symptoms from Occurring During the Day and at Night.
The Doctor will Determine how to Give Monkasta to the Child, Depending on the Child's Symptoms and the Severity of their Asthma.
Asthma is a Chronic Disease.
In Asthma, there are:
Tell the Doctor about any Health Problems and Allergies the Child has Now or has Had in the Past.
Before Giving Monkasta to the Child, Consult the Doctor or Pharmacist:
Consult the Doctor if the Child Experiences any of these Symptoms while Taking Montelukast.
Do not Give this Medicine to Children Under 2 Years of Age.
For Children and Adolescents Under 18 Years of Age, other Forms of this Medicine are Available, Suitable for the Child's Age.
Tell the Doctor or Pharmacist about all Medicines the Child is Taking Now or has Taken Recently, including those Obtained without a Prescription.
Some Medicines may Affect the Action of Monkasta or Monkasta may Affect the Action of other Medicines.
Before Giving Monkasta, Tell the Doctor if the Child is Taking:
Do not Give Monkasta 4 mg Chewable Tablets with Food; Give it at Least 1 Hour Before or 2 Hours After Food.
This Section does not Apply to Monkasta 4 mg Chewable Tablets, as they are Intended for Use in Children Aged 2 to 5 Years.
This Section does not Apply to Monkasta 4 mg Chewable Tablets, as they are Intended for Use in Children Aged 2 to 5 Years. However, the Following Information is Relevant to the Active Substance, Montelukast.
Monkasta is not Expected to Affect the Ability to Drive or Use Machines. However, Individual Reactions to the Medicine may Vary. Some Side Effects (such as Dizziness and Drowsiness) Reported with Monkasta may Affect the Ability to Drive or Use Machines in some Patients.
This Medicine Contains 1.2 mg of Aspartame in each Chewable Tablet. Aspartame is a Source of Phenylalanine. It may be Harmful if the Child has Phenylketonuria, a Rare Genetic Disorder in which Phenylalanine Builds up in the Body due to its Impaired Elimination.
This Medicine Contains Less than 1 mmol (23 mg) of Sodium per Chewable Tablet, which means it is Essentially Sodium-Free.
Always Give this Medicine Exactly as the Doctor or Pharmacist has Told you. If you are not Sure, Check with the Doctor or Pharmacist.
The Recommended Dose is one 4 mg Chewable Tablet Taken Once a Day, in the Evening.
If the Child is Taking this Medicine, Ensure they are not Taking any other Medicines that Contain the same Active Ingredient, Montelukast.
This Medicine is for Oral Use.
Chew the Tablet Before Swallowing.
Do not Give Monkasta 4 mg Chewable Tablets with Food; Give it 1 Hour Before or 2 Hours After Food.
For Advice, Contact the Child's Doctor Immediately.
In Most Cases of Overdose, no Side Effects have been Observed.
The Most Commonly Reported Symptoms of Overdose in Adults and Children are: Abdominal Pain, Drowsiness, Increased Thirst, Headache, Vomiting, and Hyperactivity.
Try to Give Monkasta as the Doctor has Prescribed. If the Child Misses a Dose, go Back to the Normal Dosing Schedule - one Chewable Tablet Once a Day.
Do not Give a Double Dose to Make up for a Missed Dose.
Monkasta is Effective in Treating Asthma in the Child only if it is Taken Regularly.
It is Important to Continue Giving the Medicine to the Child for as Long as the Doctor has Prescribed. This will Help Keep the Asthma Under Control.
If you have any Further Questions on the Use of this Medicine, Ask the Child's Doctor or Pharmacist.
Like all Medicines, this Medicine can Cause Side Effects, although not Everybody gets them.
During Clinical Trials with Montelukast 4 mg Chewable Tablets, the Most Commonly Reported Side Effects (which may Occur in up to 1 in 10 People) that were Considered to be Related to Montelukast were:
In Addition, in Clinical Trials with Montelukast 10 mg Film-Coated Tablets and 5 mg Chewable Tablets, the Following were Reported:
These Symptoms were Usually Mild and Occurred More Frequently in Patients Treated with Montelukast than in those Taking a Dummy Treatment (a Tablet that does not Contain any Medicine).
Seek Medical Attention Immediatelyif the Child Experiences any of the Following Severe Side Effects, which may Require Urgent Medical Attention.
Uncommon: may Affect up to 1 in 100 People
Rare: may Affect up to 1 in 1,000 People
Very Rare: may Affect up to 1 in 10,000 People
Very Common: may Affect more than 1 in 10 People
Common: may Affect up to 1 in 10 People
Uncommon: may Affect up to 1 in 100 People
Rare: may Affect up to 1 in 1,000 People
Very Rare: may Affect up to 1 in 10,000 People
If you Get any Side Effects, Talk to your Doctor or Pharmacist. This includes any Possible Side Effects not Listed in this Package Leaflet. You can also Report Side Effects Directly via the National Reporting System:
Department for the Monitoring of Adverse Reactions to Medicinal Products,
Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw
Tel: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
You can also Report Side Effects to the Marketing Authorization Holder.
By Reporting Side Effects, you can Help Provide more Information on the Safety of this Medicine.
Keep this Medicine out of the Sight and Reach of Children.
Do not Use this Medicine after the Expiry Date Stated on the Blister and Carton after EXP.
The Expiry Date Refers to the Last Day of the Month.
Store in the Original Package to Protect from Light.
Do not Throw Away any Medicines via Wastewater or Household Waste. Ask your Pharmacist how to Throw Away Medicines you no Longer Use. These Measures will Help Protect the Environment.
Pink, Mottled, Round, Slightly Biconvex Tablets, with a Score Line and the Number 4 on one Side.
Package: 28 and 90 Chewable Tablets in Blisters, in a Carton.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z o.o., ul. Równoległa 5, 02-235 Warsaw, Poland
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
For more Information on the Names of the Medicine in other EU Member States and the UK (Northern Ireland), Contact the Local Representative of the Marketing Authorization Holder:
KRKA-POLSKA Sp. z o.o.
ul. Równoległa 5
02-235 Warsaw
Tel. 22 57 37 500
Date of Last Revision of the Package Leaflet:07.02.2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.